Supplementary Online Content
|
|
|
- Millicent Ryan
- 6 years ago
- Views:
Transcription
1 Supplementary Online Content Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15): eequation. Applying the Five Year Kidney Failure Risk Prediction to an Individual Patient efigure 1. Derivation of Development and Validation Datasets efigure 2. Comparison of the Kaplan Meier Curve and the Cumulative Incidence Curve efigure 3. Comparison of the Mean Predicted Probability of the Cox Model and the Competing Risk Model in the Validation Cohort According to Observation Time etable 1. Variables Considered for Inclusion in the Prediction Models in the Development Dataset etable 2. Model Discrimination at 3 Years Overall and in Subgroups of Interest etable 3. Model Discrimination and Integrated Discrimination Improvement in the Validation Dataset etable 4. Net Reclassification Improvement Overall and in Relevant Subgroups in the Validation Cohort etable 5. Kidney Failure Risk Score This supplementary material has been provided by the authors to give readers additional information about their work.
2 eequation. Applying the Five Year Kidney Failure Risk Prediction to an Individual Patient The equation of the five year kidney failure risk predictor is: P = 1- S0(t) exp f(x) = 1- Save(t=1826) expf( x )-f 0 (x) =1- Save(t=1826)**exp{ *[(GFR/5)-7.22] *(male-0.56) *[ln(ACR) ] *[(age/10)-7.04] *(albumin-3.99) *(phosphorous-3.93) *(bicarbonate-25.54) *(calcium-9.35)} = 0.07 where f(x) = B1 (x1- x 1) + B ρ (x ρ- x ρ ) f(x) = (B1 x 1 + B ρ x ρ ) (B1 x1 + B ρ x ρ ) Save (t=1826) is the five-year survival rate for an individual with the average value of covariates in the risk equation (x1 x ρ ) and was in the development dataset. B1 B ρ are the regression coefficients (B1 x 1 + B ρ x ρ )represent the sum of the average values for the risk factors (B1x1 B ρ x ρ )represent the sum of the individual s risk factors Please see attached spreadsheet for risk calculations.
3 efigure 1. Derivation of Development and Validation Datasets Sunnybrook Cohort CKD Stages N=6,254 BC CKD Cohort CKD Stages N= 12,382 CKD Stages 1,2 at Baseline N= 2,805 Missing lab data N= 7,022 egfr<10 N=418 Final development data CKD Stages 3-5 N=3,449 Final validation data CKD Stages 3-5 N=4,942
4 efigure 2. Comparison of the Kaplan Meier Curve and the Cumulative Incidence Curve No at risk Events Comparison of the Kaplan Meier curve (solid black line) and the cumulative incidence curve (broken blue line). The Kaplan Meier curve represents the observed probability of kidney failure censored for death before kidney failure. The cumulative incidence curve represents the observed probability of kidney failure (death before kidney failure considered as a competing event rather than censored).
5 efigure 3. Comparison of the Mean Predicted Probability of the Cox Model and the Competing Risk Model in the Validation Cohort According to Observation Time 0.35 Probability of Event Cox Model Competing Risk Model Observation Time (Years) All participants are included in each bar (n=4,942).
6 etable 1. Variables Considered for Inclusion in the Prediction Models in the Development Dataset Variable (n) Demographics Age (3,449) Male gender (3,449) Physical Examination Weight (2,782) Systolic Blood Pressure (3,153) Diastolic Blood Pressure (3,153) Comorbid Conditions Diabetes (3,449) Hypertension (3,449) Immunologic Disease or SLE (3,449) Current or Previous Smoking (3,449) Urinary Tract Abnormality (3,449) Vascular Disease (3,449) Laboratory Data Estimated GFR (3,449) Hemoglobin (3,144) Calcium (2,891) Phosphate (2,629) Albumin (2,906) Alkaline Phosphatase (3,449) Creatinine (3,449) Sodium (3,265) Potassium (3,265) Chloride (3,265) Bicarbonate (3,169) Spot Urine Albumin-to-Creatinine Ratio (1,723) 24 Hour Urinary Protein Excretion (1,923) n is the number of subjects for whom the variable is ascertained. Spot and timed urine collections were combined to provide an n of 2,506 for quantitative urinary protein excretion.
7 etable 2. Model Discrimination at 3 Years Overall and in Subgroups of Interest Model All Age (years) Sex CKD Stage Albuminuria (mg/g) Diabetes 65 <65 Males Females Yes No Development Cohort n Model Model Model 6* Model Validation Cohort n Model Model Model 6* Model * Indicates best model. Albuminuria is defined as Albumin-to-Creatinine Ratio. C statistics are presented as measures of discrimination.
8 etable 3. Model Discrimination and Integrated Discrimination Improvement in the Validation Dataset Model C Statistic IDI (Relative)* 1 Year 3 Year 5 Year 1 Year 3 Year 5 Year Model Model (33%) 0.09 (40%) 0.10 (42%) Model (19%) 0.03 (10%) 0.02 (6%) *Comparisons are for successive models, p < for all comparisons.
9 etable 4. Net Reclassification Improvement Overall and in Relevant Subgroups in the Validation Cohort Models CKD Stage 3 CKD Stage 4 Net Reclassification (Events) n (%) Net Reclassification (Non Events) n (%) Net Reclassification Improvement n (%) (95% CI) Net Reclassification (Events) n (%) Net Reclassification (Non Events) n (%) Overall 248 (100 %) 2159 (100 %) 400 (100 %) 1695 (100 %) Net Reclassification Improvement n (%) (95% CI) Model 3 vs (30.6 %) 296 (13.7 %) 372 (44.4 %) (36.5, 52.2) 10 (2.5 %) 374 (22.1 %) 384 (24.6 %) (17.7, 31.4) Model 6 vs (36.7 %) 296 (13.7 %) 387 (50.4 %) (42.7, 58.1) 5 (1.3 %) 432 (25.5 %) 437 (26.7 %) (20.1, 33.3) Model 6 vs (8.5 %) -11 (-0.5 %) 10 (8.0 %) (2.1, 13.9) -2 (-0.5 %) 78 (4.6 %) 76 (4.1 %) (-0.5, 8.8) Age > (100 %) 1452 (100 %) 200 (100 %) 1256 (100 %) Model 3 vs (37.2 %) 233 (16.0 %) 268 (53.3 %) (40.6, 65.8) 8 (4.0 %) 264 (21.0 %) 272 (24.9 %) (14.5, 35.4) Model 6 vs (44.7 %) 226 (15.6 %) 268 (60.2 %) (48.2, 72.3) 8 (4.0 %) 288 (22.9 %) 296 (26.9 %) (16.9, 37.0) Model 6 vs. 3 7 (7.4 %) -10 (-0.7 %) -3 (6.8 %) (-2.9, 16.4) 5 (2.5 %) 31 (2.5 %) 36 (5.0 %) (-2.4, 12.5) Age < (100 %) 707 (100 %) 200 (100 %) 439 (100 %) Model 3 vs (26.6 %) 63 (8.9 %) 104 (35.5 %) (25.1, 46.0) 2 (1.0 %) 111 (25.3 %) 113 (26.3 %) (17.0, 35.6) Model 6 vs (31.8 %) 70 (9.9 %) 119 (41.7 %) (31.3, 52.2) -3 (-1.5%) 144 (32.8%) 141 (31.3 %) (22.1, 40.5) Model 6 vs (9.1 %) -1 (-0.1 %) 13 (8.9 %) (1.2, 16.7) -7 (-3.5%) 46 (10.5 %) 39 (7.0 %) (0.5, 13.5%) Males 185 (100%) 1318 (100%) 242 (100 %) 860 (100 %) Model 3 vs (34.1 %) 188 (14.3%) 251 (48.3 %) (39.9, 56.7) 7 (2.9 %) 237 (27.6 %) 244 (30.5 %) (22.6, 43.6) Model 6 vs (36.2 %) 225 (17.1 %) 292 (53.3 %) (44.8, 61.8) -12 (-5.0 %) 286 (33.3 %) 274 (28.3%) (20.2, 36.4%) Model 6 vs. 3 9 (4.9 %) 36 (2.7 %) 45 (7.6 %) (1.1, 14.1) -16 (-6.6 %) 64 (7.4 %) 48 (0.8 %) (-5.2, 6.8%) Females 63 (100%) 841 (100%) 158 (100 %) 835 (100 %)
10 Model 3 vs (20.6 %) 108 (12.8 %) 121 (33.5 %) (14.8, 52.1) 3 (1.9 %) 137 (16.4 %) 140 (18.4%) (6.4, 30.2) Model 6 vs (38.1 %) 71 (8.4 %) 95 (46.5 %) (28.8, 64.3) 17 (10.8 %) 146 (17.5 %) 163 (28.2 %) (17.1, 39.4) Model 6 vs (19.0 %) -47 (-5.6 %) -35 (13.5 %) (0.1, 26.8) 14 (8.9 %) 14 (1.7 %) 28 (10.5%) (3.0, 18.0) ACR (100 %) 945 (100 %) 86 (100 %) 713 (100 %) mg/g Model 3 vs (-25.6 %) 271 (28.7 %) 261 (3.0 %) (-11.0, 17.1) 54 (-62.8 %) 404 (56.7 %) 350 (-6.1 %) (-17.0, 6.7) Model 6 vs. 2-2 (-5.1 %) 245 (25.9 %) 243 (20.8 %) (4.7, 36.9) -40 (-46.5%) 251 (49.6 %) 211 (3.1 %) (-9.8, 16.1) Model 6 vs. 3 8 (20.5 %) -20 (-2.1 %) -12 (18.4 %) (3.6, 33.2) 12 (14.0 %) -21 (-2.9 %) -9 (11.0 %) (-1.6, 23.6) ACR > (100 %) 618 (100 %) 299 (100 %) 679 (100 %) mg/g Model 3 vs (47.7 %) -265 (-42.9 %) -171 (4.8%) (-3.1, 12.9) 78 (26.1 %) -136 (-30.0 %) -58 (-3.9%) (-10.5, 2.6%) Model 6 vs (50.8 %) -209 (-33.8 %) -109 (16.9 %) (8.6, 25.3) 54 (18.1 %) -92 (-13.6 %) -38 (4.5 %) (-2.8, 11.8) Model 6 vs (6.6 %) 38 (6.1 %) 51 (12.7 %) (5.3, 20.2) -19 (-6.4 %) 110 (16.2 %) 91 (9.8 %) (4.4, 15.3) Diabetes 156 (100 %) 762 (100 %) 230 (100 %) 579 (100 %) Model 3 vs (35.3 %) 66 (8.7 %) 121 (43.9 %) (33.5, 54.3) 19 (8.3 %) 99 (17.1 %) 118 (25.4 %) (15.6, 35.1) Model 6 vs (39.7 %) 66 (8.7 %) 128 (48.4 %) (38.4, 58.4) 11 (4.8 %) 135 (23.3 %) 146 (28.1 %) (18.9, 37.6) Model 6 vs (7.7 %) -5 (-0.7 %) 7 (7.0 %) (-0.4, 14.5) -4 (-1.7 %) 41 (7.1 %) 37 (5.3%) (-1.0, 11.7) No Diabetes 92 (100 %) 1397 (100 %) 170 (100 %) 1116 (100 %) Model 3 vs (22.8 %) 231 (16.5 %) 252 (39.3 %) (26.8, 51.8) -9 (-5.3 %) 275 (24.6 %) 266 (19.3 %) (9.4, 29.3) Model 6 vs (31.5 %) 231 (16.5 %) 260 (48.0 %) (35.2,60.8) -6 (-3.5 %) 297 (26.6 %) 291 (23.1 %) (13.6, 36.6) Model 6 vs. 3 9 (9.8 %) -6 (-0.4 %) 3 (9.4 %) (-0.9, 19.6) 2 (1.2 %) 37 (3.3 %) 39 (4.5 %) (-3.1, 12.1) Risk categories for CKD stage 3 are 0%-5%, 5%-15%, and >15% over 5 years, and for CKD stage 4 are 0%-10%, 10%-20%, and >20% over 2 years.
11 etable 5. Kidney Failure Risk Score P (event) = Probability of kidney failure at 5 years Risk Factor Categories Points Risk Factor Categories Points egfr Albumin <= >= Phosphorous < > Bicarbonate Male < 18-7 No Yes ACR >25 0 <30 0 Calcium <= > Age >9.6 2 < > 90 10
12 Interpretation Score < -41 = P (Kidney Failure) > 90% Score > -3 = P (Kidney Failure) < 5% Between -3 and -41, please refer to the chart below Score P(event) Score P(event) % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % A smartphone app is available at
Supplementary Online Content
Supplementary Online Content James MT, Neesh P, Hemmelgarn BR, et al. Derivation and external validation of prediction models for advanced chronic kidney disease following acute kidney injury. JAMA. doi:10.1001/jama.2017.16326
Supplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
Supplementary Online Content
Supplementary Online Content Malik S, Zhao Y, Budoff M, et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic
Supplemental Table 1. Standardized Serum Creatinine Measurements. Supplemental Table 3. Sensitivity Analyses with Additional Mortality Outcomes.
SUPPLEMENTAL MATERIAL Supplemental Table 1. Standardized Serum Creatinine Measurements Supplemental Table 2. List of ICD 9 and ICD 10 Billing Codes Supplemental Table 3. Sensitivity Analyses with Additional
Chapter Two Renal function measures in the adolescent NHANES population
0 Chapter Two Renal function measures in the adolescent NHANES population In youth acquire that which may restore the damage of old age; and if you are mindful that old age has wisdom for its food, you
AN ESTIMATED 23 MILLION
ORIGINAL CONTRIBUTION ONLINE FIRST A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure Navdeep Tangri, MD, FRCPC Lesley A. Stevens, MD, MS, FRCPC John Griffith, PhD Hocine Tighiouart,
Supplementary Online Content
Supplementary Online Content Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B 1. JAMA. 9;3(19):119-1. etable 1. Circulating Levels of B
Supplementary Online Content
Supplementary Online Content McEvoy JW, Chen Y, Ndumele CE, et al. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. JAMA Cardiol.
Chronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
>4000 mg/dl (=20000/(500/100)) >615 mmol/l (=20000/(65*0.5))
Supplemental Table 1 Thresholds to define outliers of lab values in screening test for proteinuria Type of screening test Unit Threshold for Outliers References 24 hour urine albumin mg/d >20000 experienced
CKDinform: A PCP s Guide to CKD Detection and Delaying Progression
CKDinform: A PCP s Guide to CKD Detection and Delaying Progression Learning Objectives Describe suitable screening tools, such as GFR and ACR, for proper utilization in clinical practice related to the
Chapter 1: CKD in the General Population
Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table
egfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
Supplementary Online Content
Supplementary Online Content Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based
BASELINE CHARACTERISTICS OF THE STUDY POPULATION
Study Summary DAILY ORAL SODIUM BICARBONATE PRESERVES GLOMERULAR FILTRATION RATE BY SLOWING ITS DECLINE IN EARLY HYPERTENSIVE NEPHROPATHY This was a 5-year, single-center, prospective, randomized, placebo-controlled,
SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.
Supplementary Figure S1. Cohort definition flow chart. Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not
Individual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
Delacroix et al Renal effects of renal denervation Supplementary Figure 1: Changes in Ambulatory Blood Pressures and Heart Rate
Supplementary Figure 1: Changes in Ambulatory Blood Pressures and Heart Rate Supplementary Table 1: Ranking each patient based on the number of measurements showing a numerical improvement. Rank at each
Stages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
Evaluation of Chronic Kidney Disease KDIGO. Paul E de Jong University Medical Center Groningen The Netherlands
Evaluation of Chronic Kidney Disease Paul E de Jong University Medical Center Groningen The Netherlands Evaluation and Management of CKD 1. Definition and classification of CKD 2. Definition and impact
1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
Composite Performance Report
Composite Performance Report 10 9 91% 8 7 65% 68% 65% 6 56% 5 4 3 2 44% 37% 48% 31% 19% 29% 1 6% Key: Report Measure Name Cohort Target Cohort Definition Formula 1 Control Blood Pressure All patients who
Supplementary Online Content
Supplementary Online Content Clark WF, Sontrop JM, Huang S-H et al. Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney Disease: the CKD WIT Randomized
Supplementary Online Content
Supplementary Online Content Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney
Supplementary Material. Serum Chloride is an Independent Predictor of Mortality in Hypertensive Patients
Supplementary Material Serum Chloride is an Independent Predictor of Mortality in Hypertensive Patients Linsay McCallum,* Panniyammakal Jeemon,* Claire E Hastie, Rajan K Patel, Catherine Williamson, Adyani
Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
A n aly tical m e t h o d s
a A n aly tical m e t h o d s If I didn t go to the screening at Farmers Market I would not have known about my kidney problems. I am grateful to the whole staff. They were very professional. Thank you.
Supplementary Online Content
Supplementary Online Content Zusterzeel R, Selzman KA, Sanders WE, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patientlevel data. Published online
QUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney
2017 American Medical Association. All rights reserved.
Supplementary Online Content Borocas DA, Alvarez J, Resnick MJ, et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3
Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
Renal tubular secretion in chronic kidney disease: description, determinants, and outcomes. Astrid M Suchy-Dicey
Renal tubular secretion in chronic kidney disease: description, determinants, and outcomes Astrid M Suchy-Dicey A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
Primary Care Approach to Management of CKD
Primary Care Approach to Management of CKD This PowerPoint was developed through a collaboration between the National Kidney Foundation and ASCP. Copyright 2018 National Kidney Foundation and ASCP Low
Summary of Recommendation Statements Kidney International Supplements (2013) 3, 5 14; doi: /kisup
http://www.kidney-international.org & 2013 DIGO Summary of Recommendation Statements idney International Supplements (2013) 3, 5 14; doi:10.1038/kisup.2012.77 Chapter 1: Definition and classification of
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Rawshani Aidin, Rawshani Araz, Franzén S, et al. Risk factors,
Supplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
Supplementary Online Content
Supplementary Online Content Engebretson SP, Hyman LG, Michalowicz BS, et al. The effect of nonsurgical periodontal therapy on hemoglobin A1c levels among persons with type 2 diabetes and chronic periodontitis:
Supplementary Online Content
Supplementary Online Content Schnabel RB, Aspelund T, Li G, et al. Validation of an atrial fibrillation risk algorithm in whites and African Americans. Arch Intern Med. 2010;170(21):1909-1917. eappendix.
S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
Concept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA
Concept and General Objectives of the Conference: Prognosis Matters Andrew S. Levey, MD Tufts Medical Center Boston, MA General Objectives Topics to discuss What are the key outcomes of CKD? What progress
Nephrology referral - Does my patient need it? Disclosure
Nephrology referral - Does my patient need it? Sophia Chou, MD MSc March 10, 2018 Faculty: Sophia Chou Disclosure Relationships with commercial interest: None Potential conflict of interest: None 1 Objectives
Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
Disclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
Diabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
Disclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
Scoring Life Insurance Applicants Laboratory Results, Blood Pressure and Build to Predict All-Cause Mortality Risk
Copyright E 2012 Journal of Insurance Medicine J Insur Med 2012;43:169 177 MORTALITY Scoring Life Insurance Applicants Laboratory Results, Blood Pressure and Build to Predict All-Cause Mortality Risk Michael
Chronic kidney disease (CKD) affects more than 26
A Simple Tool to Predict End-Stage Renal Disease within 1 Year in Elderly Adults with Advanced Chronic Kidney Disease Paul E. Drawz, MD, MHS, MS,* Puja Goswami, MD, Reem Azem, BA, Denise C. Babineau, PhD,
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,
Outline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
Kidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
Supplementary Online Content
Supplementary Online Content Giannakeas V, Sopik V, Narod SA. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy. JAMA Netw Open. 2018;1(4):e181100.
Supplementary Online Content
Supplementary Online Content Nikolova AP, Hitzeman TC, Baum R, et al. Association of a novel diagnostic biomarker, the plasma cardiac bridging integrator 1 score, with heart failure with preserved ejection
Supplementary Online Content
Supplementary Online Content Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease: the Renal Substudy of the China Stroke Primary Prevention Trial. JAMA
Lucia Cea Soriano 1, Saga Johansson 2, Bergur Stefansson 2 and Luis A García Rodríguez 1*
Cea Soriano et al. Cardiovascular Diabetology (2015) 14:38 DOI 10.1186/s12933-015-0204-5 CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Cardiovascular events and all-cause mortality in
Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database
open access Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database Yana Vinogradova, 1 Carol Coupland, 1 Peter Brindle, 2,3 Julia Hippisley-Cox
BASELINE CHARACTERISTICS OF THE STUDY POPULATION
COMPARISON OF TREATING METABOLIC ACIDOSIS IN CKD STAGE 4 HYPERTENSIVE KIDNEY DISEASE WITH FRUITS & VEGETABLES OR SODIUM BICARBONATE This was a 1-year, single-center, prospective, randomized, interventional
SPRINT: Consequences for CKD patients
SPRINT: Consequences for CKD patients 29 e Workshop Nierziekten Papendal 2018 December 12, 2018 MICHAEL ROCCO, MD, MSCE VARDAMAN M. BUCKALEW JR. PROFESSOR OF MEDICINE PROFESSOR OF PUBLIC HEALTH SCIENCES
Supplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
A New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta
A New Approach for Evaluating Renal Function and Predicting Risk William McClellan, MD, MPH Emory University Atlanta Goals Understand the limitations and uses of creatinine based measures of kidney function
Supplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
Supplementary Online Content
Supplementary Online Content Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among people with and without diabetes. JAMA. doi:10.1001/jama.2013.1644.
Quality of Care in Early Stage Chronic Kidney Disease
Quality of Care in Early Stage Chronic Kidney Disease 2012 2013 Supplementary Report to the 2015 Alberta Annual Kidney Care Report Kidney Health Strategic Clinical Network December 22, 2015 For more information
New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
CHRONIC KIDNEY DISEASE WHY WOMEN MAY BE AT RISK?
CHRONIC KIDNEY DISEASE WHY WOMEN MAY BE AT RISK? Dr. Judy A Geissler, DNP, APNP, FNP-BC, CNN Vascular Access Advanced Practice Provider Employer- Medical College of Wisconsin No financial disclosures Barbara
Outpatient Management of Chronic Kidney Disease for the Internist
Outpatient Management of Chronic Kidney Disease for the Internist Annual Meeting of Maryland Chapter of the American College of Physicians February 3, 2018 MARY (TESSIE) BEHRENS, MD, FACP, FASN, FNKF MID-ATLANTIC
Supplementary Online Content
Supplementary Online Content Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes:
Section 1: 1: Trends. Section 2: 2: Comparisons to to Overall Portland Area Area Results for for
Section 1: 1: Trends 1 Patients in the Diabetes Register 2 Gender of Patients with Diabetes 2 Age of Patients with Diabetes 3 Diabetes Type 3 Duration of Diabetes 4 Weight Control 5 Hemoglobin A1c 6 Blood
Creatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC
Creatinine & egfr A Clinical Perspective Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC CLINICAL CONDITIONS WHERE ASSESSMENT OF GFR IS IMPORTANT Stevens et al. J Am Soc Nephrol 20: 2305
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
Applying clinical guidelines treating and managing CKD
Applying clinical guidelines treating and managing CKD Develop patient treatment plan according to level of severity. Source: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
Diagnostic methods 2: receiver operating characteristic (ROC) curves
abc of epidemiology http://www.kidney-international.org & 29 International Society of Nephrology Diagnostic methods 2: receiver operating characteristic (ROC) curves Giovanni Tripepi 1, Kitty J. Jager
Supplementary Online Content
Supplementary Online Content Wolters FJ, Li L, Gutnikov SA, Mehta Z, Rothwell PM. Medical attention seeking after transient ischemic attack and minor stroke in relation to the UK Face, Arm, Speech, Time
Long-term outcomes in nondiabetic chronic kidney disease
original article http://www.kidney-international.org & 28 International Society of Nephrology Long-term outcomes in nondiabetic chronic kidney disease V Menon 1, X Wang 2, MJ Sarnak 1, LH Hunsicker 3,
Nice CKD Clinical Guidelines 2014 The challenges and benefits they may bring toprimary care
Nice CKD Clinical Guidelines 2014 The challenges and benefits they may bring toprimary care Paula D Souza Senior CKD Nurse Specialist Royal Devon and Exeter Healthcare Trust Introduction Background What
Supplementary Online Content
Supplementary Online Content Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova N. Trends in infective endocarditis in California and New York State, 1998-2013. JAMA. doi:10.1001/jama.2017.4287
USRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
Supplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Chen CL, Lin GA, Bardach NS, et al. Preoperative medical testing
Optimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
CKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
SUPPLEMENTARY DATA. Supplementary Table S1. Clinical characteristics of the study subjects.*
Supplementary Table S1. Clinical characteristics of the study subjects.* T2D ND n (F/M) 66 (21/45) 25 (7/18) Age (years) 61.8 ± 6.9 49.4 ± 7.3 # Body weight (kg) 95 ± 16 105 ± 13 # Body mass index (kg.
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression Arasu Gopinath, MD Clinical Nephrologist, Medical Director, Jordan Landing Dialysis Center Objectives: Identify the most important risks
Rationale: Objectives: Indication: Diabetes Mellitus, Type 2 Study Investigators/Centers: 300 physicians in 292 clinics Research Methods: Data Source:
GSK Medicine: N/A Study No.: 112255 Title: A Korean, multi-center, nation-wide, cross-sectional, epidemiology study to identify prevalence of diabetic nephropathy in hypertensive patients with type 2 diabetes
Supplementary Table 1. Criteria for selection of normal control individuals among healthy volunteers
Supplementary Table 1. Criteria for selection of normal control individuals among healthy volunteers Medical parameters Cut-off values BMI (kg/m 2 ) 25.0 Waist (cm) (Men and Women) (Men) 85, (Women) 90
Chronic Kidney Disease: Optimal and Coordinated Management
Chronic Kidney Disease: Optimal and Coordinated Management Michael Copland, MD, FRCPC Presented at University of British Columbia s 42nd Annual Post Graduate Review in Family Medicine Conference, Vancouver,
Appendix. Supplementary figures and tables
This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix. Supplementary figures and tables Figure A1. Flowchart describing patient
Supplementary Online Content
Supplementary Online Content Henson KE, Brock R, Charnock J, Wickramasinghe B, Will O, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. Published online November 21, 2018.
Slowing the Progression of Chronic Kidney Disease. Through the Treatment of Metabolic Acidosis
Slowing the Progression of Chronic Kidney Disease Through the Treatment of Metabolic Acidosis Forward Looking Statements Any statements in this presentation that are not statements of historical facts
PEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW. Kristine Hommel Department of nephrology, Herlev Hospital, Denmark 17-Nov-2015
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
Identifying and Managing Chronic Kidney Disease: A Practical Approach
Identifying and Managing Chronic Kidney Disease: A Practical Approach S. Neil Finkle, MD, FRCPC Associate Professor Division of Nephrology, Department of Medicine, Dalhousie University Program Director,
The positive side of overdiagnosis
The positive side of overdiagnosis Does an immediate comprehensive panel of laboratory tests in outpatient care improve patient outcomes? Bram Vrijsen, Maarten ten Berg, Christiana Naaktgeboren, Jolande